

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin Formulation

Manufacturer or supplier's details

Company : MSD

Address : No. 485 Jing Tai Road
Pu Tuo District - Shanghai - China 200331

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : oily
Colour : light yellow
Odour : characteristic

May be harmful if swallowed. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification

Acute toxicity (Oral) : Category 5

Specific target organ toxicity - single exposure : Category 2

Specific target organ toxicity - repeated exposure : Category 2

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

GHS label elements

Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	<p>H303 May be harmful if swallowed. H371 May cause damage to organs. H373 May cause damage to organs through prolonged or repeated exposure. H410 Very toxic to aquatic life with long lasting effects.</p>
Precautionary statements	:	<p>Prevention: P260 Do not breathe mist or vapours. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P273 Avoid release to the environment.</p> <p>Response: P301 + P317 IF SWALLOWED: Get medical help. P308 + P316 IF exposed or concerned: Get emergency medical help immediately. P391 Collect spillage.</p> <p>Storage: P405 Store locked up.</p> <p>Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.</p>

Physical and chemical hazards

Not classified based on available information.

Health hazards

May be harmful if swallowed. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 6097530-00017 Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Ivermectin	70288-86-7	>= 1 < 2.5
2,6-Di-tert-butyl-p-cresol	128-37-0	>= 0.25 < 1

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : May be harmful if swallowed.
May cause damage to organs.
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 6097530-00017 Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis	
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal	
		Further information: Skin			
2,6-Di-tert-butyl-p-cresol	128-37-0	Wipe limit TWA (Inhal- able fraction and vapor)	300 µg/100 cm ² 2 mg/m ³	Internal ACGIH	

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

posable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hand protection

Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: oily
Colour	: light yellow
Odour	: characteristic
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: 167.5 °C
Flash point	: 219.2 °C
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 6097530-00017 Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Relative vapour density	: No data available
Relative density	: 0.88 - 0.92
Density	: No data available
Solubility(ies)	
Water solubility	: practically insoluble
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: Not applicable

10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation Skin contact Ingestion Eye contact
-----------------	--

Acute toxicity

May be harmful if swallowed.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Product:

Acute oral toxicity : Acute toxicity estimate: 5,000 mg/kg
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Ivermectin:

Species : Rabbit
Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

||| Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ivermectin:

||| Species : Rabbit
||| Result : Mild eye irritation

2,6-Di-tert-butyl-p-cresol:

||| Species : Rabbit
||| Result : No eye irritation
||| Method : OECD Test Guideline 405
||| Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ivermectin:

||| Exposure routes : Dermal
||| Species : Humans
||| Result : Does not cause skin sensitisation.

2,6-Di-tert-butyl-p-cresol:

||| Test Type : Human repeat insult patch test (HRIPT)
||| Exposure routes : Skin contact
||| Species : Humans
||| Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ivermectin:

||| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
||| Result: negative
||| Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Ivermectin:

Species : Rat
Application Route : Oral
NOAEL : 1.5 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

Species : Mouse
Application Route : Oral
NOAEL : 2.0 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

Reproductive toxicity

Not classified based on available information.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Components:

Ivermectin:

Effects on fertility

: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development

: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

2,6-Di-tert-butyl-p-cresol:

Effects on fertility

: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

May cause damage to organs.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Components:

Ivermectin:

Target Organs	:	Central nervous system
Assessment	:	Causes damage to organs.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Ivermectin:

Target Organs	:	Central nervous system
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment	:	No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.
------------	---	--

Repeated dose toxicity

Components:

Ivermectin:

Species	:	Dog
NOAEL	:	0.5 mg/kg
LOAEL	:	1 mg/kg
Application Route	:	Oral
Exposure time	:	14 Weeks
Target Organs	:	Central nervous system
Symptoms	:	Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species	:	Monkey
NOAEL	:	1.2 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Remarks	:	No significant adverse effects were reported

Species	:	Rat
NOAEL	:	0.4 mg/kg
LOAEL	:	0.8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	spleen, Bone marrow, Kidney

2,6-Di-tert-butyl-p-cresol:

Species	:	Rat
NOAEL	:	25 mg/kg

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 6097530-00017 Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Application Route : Ingestion
Exposure time : 22 Months

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.
Eye contact : Remarks: May irritate eyes.
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10,000
M-Factor (Chronic aquatic toxicity) : 10,000

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0.57 mg/l
Exposure time: 96 h
Method: Directive 67/548/EEC, Annex V, C.1.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 6097530-00017 Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.48 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	1
Toxicity to fish (Chronic toxicity)	:	NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l Exposure time: 30 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.316 mg/l Exposure time: 21 d
M-Factor (Chronic aquatic toxicity)	:	1
Toxicity to microorganisms	:	EC50: > 10,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

Persistence and degradability

Components:

Ivermectin:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d
------------------	---	--

2,6-Di-tert-butyl-p-cresol:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 4.5 % Exposure time: 28 d Method: OECD Test Guideline 301C
------------------	---	--

Bioaccumulative potential

Components:

Ivermectin:

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 6097530-00017 Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-octanol/water : log Pow: 5.1

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0	Revision Date: 2025/04/14	SDS Number: 6097530-00017	Date of last issue: 2024/09/28 Date of first issue: 2020/06/30
----------------	------------------------------	------------------------------	---

Environmentally hazardous : yes

IMDG-Code

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (ivermectin, 2,6-Di-tert-butyl-p-cresol)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (ivermectin, 2,6-Di-tert-butyl-p-cresol)
Class	: 9
Packing group	: III
Labels	: 9
Marine pollutant	: no

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals	: This product is not listed in the catalogue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of determination.
----------------------------------	---

Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218) : Not listed

Hazardous Chemicals for Priority Management under SAWS : Not listed

|| Catalogue of Specially Controlled Hazardous Chemi- : Not listed

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version
7.0

Revision Date:
2025/04/14

SDS Number:
6097530-00017

Date of last issue: 2024/09/28
Date of first issue: 2020/06/30

|||cals

|||List of Explosive Precursors

: Not listed

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export : Not listed

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

Regulations of Ozone Depleting Substances Management

|||List of Controlled Ozone Depleting Substances Import and Export : Not listed

|||List of Controlled Ozone Depleting Substances : Not listed

Environmental Protection Law

|||List of Priority Controlled Chemicals : Not listed

|||List of Key Controlled New Pollutants : Not listed

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2025/04/14

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Ivermectin Formulation

Version 7.0	Revision Date: 2025/04/14	SDS Number: 6097530-00017	Date of last issue: 2024/09/28 Date of first issue: 2020/06/30
----------------	------------------------------	------------------------------	---

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN